$IINX Ionix Technology, Inc. Announces Third Quarter 2020

New Post Public Reply Private Reply Replies (0) Message Board
Lee Adams
217
$IINX Ionix Technology, Inc. Announces Third Quarter 2020 Financial Results

LAS VEGAS, NV, May 18, 2020 (GLOBE NEWSWIRE) -- Ionix Technology, Inc. (OTCQB: IINX), ("Ionix Technology", "IINX" or "the Company", a business aggregator in photoelectric display and smart energy fields, announced its financial results for the three months ended March 31, 2020.

Third Quarter 2020 Financial Highlights:

Total revenues were $2,752,170 and $2,894,802 respectively for the three months ended March 31, 2020 and 2019.

Gross profit was $245,652 and $623,422, respectively for the three months ended March 31, 2020 and 2019.

During the three months ended March 31, 2020 and 2019 net income (loss) was $(636,222) and $21,064, respectively.
“From early February to the end of March, we closed all factories to limit the spread of COVID-19. The shutdown of business affected the operational and financial performance of IINX for the third quarter of 2020,” said Mr. Cheng Li, Chairman and CEO of Ionix Technology. “However, since restarting operations near the end of March, the Company’s financial performances have been recovering continuously as transportations returned to normal, all of the supply chains were restored and all of our factories resumed operations.”

Mr. Li continued, “While the near-term market environment will likely continue to be challenging, we believe we are well-positioned to navigate current conditions based on our continuous investment in research and development of industry-leading emerging technologies, our durable business model and our talented team. We will continue to operate at the highest efficiency and remain committed to working diligently on behalf of our investors.”

Revenue

During the three months ended March 31, 2020 and 2019, total revenues were $2,752,170 and $2,894,802, respectively. The total revenues decreased by $142,632 or 5% from the three months ended March 31, 2019 to the three months ended March 31, 2020.

During the three months ended March 31, 2020, COVID-19 affected the operational and financial performance of the Company as the PRC imposed a national economic shutdown to limit the spread of COVID-19 from early February to mid-March. At the same time the Company temporarily closed all of its factories while transportations in or out of them were suspended, and experienced an unprecedented “supplier chain break”. Since the restart of operations near the end of March, the Company’s financial performances have been recovering continuously as transportations have returned to normal, the supply chain wasrestored and all of its factories resumed working.

During the nine months ended March 31, 2020 and 2019, total revenues were $17,585,468 and $7,841,437, respectively. The total revenues increased by $9,744,031 or 124% from the nine months ended March 31, 2019 to the nine months ended March 31, 2020.

Among the significant increase of $9,744,031 in total revenues for the nine months ended March 31, 2020, $11,581,460 was the revenue from Fangguan Electronics which was acquired on December 27, 2018. The acquisition expanded the Company’s operations in the fields of LCM in the PRC and significantly increased the volume of goods (LCD, etc.) being sold.

The increase in total revenues due to acquisition of Fangguan Electronics was partially offset by the decreases of $1,837,429 related to the other business (excluding Fangguan Electronics) for the nine months ended March 31, 2020 compared to 2019. After Fangguan Electronics was acquired, all business of Fangguan Photoelectric was replaced by Fangguan Electronics, which caused total revenues to decrease by $2,407,535 respectively for the nine months ended March 31, 2020.

Cost of Revenue

During the three months ended March 31, 2020 and 2019, the total cost of revenues was $2,506,518 and $2,271,380, respectively. The total cost of revenues increased by $235,138 or 10% from the three months ended March 31, 2019 to the three months ended March 31, 2020.

During the nine months ended March 31, 2020 and 2019, the total cost of revenues was $14,850,194 and $6,618,015 respectively. The total cost of revenues increased by $8,232,179 or 124% from the nine months ended March 31, 2019 to the nine months ended March 31, 2020.

Among the significant increase of $8,232,179 in total cost of revenues for the nine months ended March 31, 2020 compared to 2019, the $9,991,514 increase can be directly attributed to the acquisition of Fangguan Electronics on December 27, 2018.

The increase in total cost of revenues due to acquisition of Fangguan Electronics was partially offset by the decreases of $1,759,335 related to the other business (excluding Fangguan Electronics) for the nine months ended March 31, 2020 compared to 2019. After Fangguan Electronics was acquired, all business of Fangguan Photoelectric was replaced by Fangguan Electronics, which caused total cost of revenues to decrease by $2,076,990 for the nine months ended March 31, 2020.

Gross Profit

During the three months ended March 31, 2020 and 2019, the gross profit was $245,652 and $623,422, respectively. Gross profit margin was at 9% during the three months ended March 31, 2020 as compared to 22% for the three months ended March 31, 2019.

The decrease in both gross profit and gross profit margin can be attributed to the fact that starting from second fiscal quarter, the Company adopted the new business strategy to have low gross profits and increase sales volume.

Selling, General and Administrative Expenses

During the three months ended March 31, 2020 and 2019, selling, general and administrative expenses were $499,616 and $392,367, respectively.

The difference can be attributed to the depreciation and amortization expenses, payroll expenses, professional fees and other expenses incurred during the three months ended March 31, 2020 after Fangguan Electronics became a variable interest entity of the Company on December 27, 2018.

Research and Development Expenses

During the three months ended March 31, 2020 and 2019, research and development expenses were $139,029 and $158,562, respectively.

Net Income (Loss)

During the three months ended March 31, 2020 and 2019 net income (loss) was $(636,222) and $21,064, respectively.

The change can be attributed to the decrease in gross profits and the increase of expenses during the three months ended March 31, 2020.

Cash and Financial Position

As of March 31, 2020, the Company had cash and cash equivalents of $1,834,763, compared to $509,615 as of June 30, 2019.

The Company had a working capital of $1,828,672 as of March 31, 2020 compared to working capital of $717,977 as of June 30, 2019.

During the nine months ended March 31, 2020, net cash provided by operating activities was $641,370 compared to net cash used in operating activities of $900,588 for the nine months ended March 31, 2019. The change was mainly due to the increase of $5,641 in the net income, an increase of $766,310 resulting from adjustments to net income for non-cash items, and a decrease of $770,007 in cash outflow from changes in operating assets and liabilities in the nine months ended March 31, 2020 compared to same period in 2019.

During the nine months ended March 31, 2020, net cash used in investing activities was $71,895 compared to net cash provided by investing activities of $649,216 for the nine months ended March 31, 2019. Cash used in the acquisition of the equipment increased by $155,235 in the nine months ended March 31, 2020 compared to same period in 2019 due to acquisition of Fangguan Electronics. In addition, the Company also received cash of $687,591 in December 2018 due to the acquisition of Fangguan Electronics.

During the nine months ended March 31, 2020, cash provided by financing activities was $787,503, which was primarily due to the proceeds received from issuance of convertible notes. During the nine months ended March 31, 2019, the Company received $588,062 in cash for financing activities, which was primarily attributable to the proceeds from the related party loans offsetting by the return of capital to non-controlling interests.

About Ionix Technology, Inc.

Ionix Technology, Inc. is a holding company that is principally engaged in the photoelectric display and smart energy industries. The company has five operating subsidiaries: Changchun Fangguan Electronics Technology Co., Ltd, a company which has been focusing on R&D, manufacturing and marketing LCM and LCD. Changchun Fangguan Photoelectric Display Technology Co., Ltd, a company which specializes in developing, designing, and selling TN and STN LCD, STN, CSTN, and TFT LCD modules as well as other related products; Shenzhen Baileqi Electronic Technology Co., Ltd, a company which specializes in LCD slicing, filling, researching and designing, and selling of LCD Modules (LCM) and PCBs; Lisite Science Technology (Shenzhen) Co., Ltd., a company engaged in the marketing and selling of intelligent electronic devices; and Dalian Shizhe New Energy Technology Co., Ltd., a company engaged in the new energy support service, and operating the photovoltaic power generation, electric vehicles and charging piles with corresponding operation and maintenance and three dimensional parking. Currently, IINX has embarked on the layout of industrialization and marketization of front end materials and back end modules of liquid crystal displays and applications of flexible folding display technology by taking Fangguan Electronics as production bases, to seize the market share of OLED high technology.

To learn more, please visit our website: www.theiinx.com

Safe Harbor Statement

This news release contains "forward-looking statements" as that term is defined in the United States Securities Act of 1933, as amended and the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements, including beliefs, plans, expectations or intentions regarding the future, and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors, such as the inherent uncertainties associated with new business opportunities and development stage companies. Ionix Technology assumes no obligation to update the forward-looking statements. Although Ionix Technology believes that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that they will prove to be accurate. Investors should refer to the risk factors disclosure outlined in Ionix Technology's annual report on Form 10-K for the most recent fiscal year, quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the U.S. Securities and Exchange Commission.

IR Contact:

Dragon Gate Investment Partners LLC

Tel: +1(646)-801-2803

Email: iinx@dgipl.com



(financial tables follow; please see 10-Q filed with SEC May 15, 2020 for notes to financial statements which are an integral part of the financial statements)

IONIX TECHNOLOGY, INC.
CONSOLIDATED BALANCE SHEETS
(Unaudited)

March 31, 2020 June 30, 2019
ASSETS
Current Assets:
Cash and cash equivalents (Note 3 at VIE) $ 1,834,763 $ 509,615
Notes receivable (Note 3 at VIE) 23,721 120,182
Accounts receivable - non-related parties (Note 3 at VIE) 3,494,207 3,639,030
- related parties 420,906 340,026
Inventory (Note 3 at VIE) 3,045,127 3,379,146
Advances to suppliers - non-related parties (Note 3 at VIE) 354,820 129,423
- related parties 264,797 269,498
Prepaid expenses and other current assets (Note 3 at VIE) 593,122 269,495
Total Current Assets (Note 3 at VIE) 10,031,463 8,656,415

Property, plant and equipment, net (Note 3 at VIE) 6,812,910 7,508,637
Right-of-use assets – operating leases 20,825 -
Intangible assets, net (Note 3 at VIE) 1,430,449 1,496,399
Deferred tax assets (Note 3 at VIE) 51,460 54,361
Total Assets (Note 3 at VIE) $ 18,347,107 $ 17,715,812

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Short-term bank loan (Note 3 at VIE) $ 2,540,543 $ 2,618,296
Accounts payable (Note 3 at VIE) 2,569,420 2,732,327
Advance from customers (Note 3 at VIE) 59,165 114,158
Convertible notes payable, net of debt discount and loan cost 347,427 -
Derivative liability 446,852 -
Due to related parties (Note 3 at VIE) 2,032,723 2,105,338
Operating lease liabilities – current portion 7,646 -
Accrued expenses and other current liabilities (Note 3 at VIE) 199,015 368,319
Total Current Liabilities (Note 3 at VIE) 8,202,791 7,938,438

Operating lease liabilities 12,462 -
Total Liabilities (Note 3 at VIE) 8,215,253 7,938,438

COMMITMENT AND CONTINGENCIES

Stockholders’ Equity:
Preferred stock, $.0001 par value, 5,000,000 shares authorized,
5,000,000 shares issued and outstanding 500 500
Common stock, $.0001 par value, 195,000,000 shares
authorized, 114,193,057 and 114,003,000 shares issued and
outstanding as of March 31, 2020 and June 30, 2019,
respectively 11,419 11,400
Additional paid in capital 9,299,825 8,829,487
Retained earnings 750,578 539,866
Accumulated other comprehensive loss (372,429 ) (45,840 )
Total Stockholders' Equity attributable to the Company 9,689,893 9,335,413
Noncontrolling interest 441,961 441,961
Total Stockholders’ Equity 10,131,854 9,777,374
Total Liabilities and Stockholders’ Equity $ 18,347,107 $ 17,715,812
IONIX TECHNOLOGY, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(Unaudited)

For the Three Months Ended For the Nine Months Ended
March 31, March 31,
2020 2019 2020 2019

Revenues (See Note 2 and Note 9 for
related party amounts) $ 2,752,170 $ 2,894,802 $ 17,585,468 $ 7,841,437

Cost of Revenues (See Note 9 for related
party amounts) 2,506,518 2,271,380 14,850,194 6,618,015

Gross profit 245,652 623,422 2,735,274 1,223,422

Operating expenses
Selling, general and administrative expense 499,616 392,367 1,378,241 686,132
Research and development expense 139,029 158,562 645,880 158,562
Total operating expenses 638,645 550,929 2,024,121 844,694

Income (loss) from operations (392,993 ) 72,493 711,153 378,728

Other income (expense):
Interest expense, net of interest income (213,267 ) (34,412 ) (470,500 ) (34,412 )
Subsidy income - - 50,018 -
Change in fair value of derivative liability (44,850 ) - 86,602 -
Loss on extinguishment of debt (15,074 ) - (15,074 ) -
Total other expense (273,191 ) (34,412 ) (348,954 ) (34,412 )

Income (loss) before income tax provision (666,184 ) 38,081 362,199 344,316

Income tax provision (benefit) (29,962 ) 17,017 151,487 139,245
Net income (loss) (636,222 ) 21,064 210,712 205,071

Other comprehensive income (loss)
Foreign currency translation adjustment (165,507 ) 56,484 (326,589 ) 28,523
Comprehensive income (loss) $ (801,729 ) $ 77,548 $ (115,877 ) $ 233,594


Earnings (Loss) Per Share - Basic $ (0.01 ) $ 0.00 $ 0.00 $ 0.00
Weighted average number of common
shares outstanding - Basic 114,104,735 114,003,000 114,036,665 104,148,985

Earnings (Loss) Per Share - Diluted $ (0.01 ) $ 0.00 $ 0.00 $ 0.00
Weighted average number of common
shares outstanding - Diluted 113,913,240 114,003,000 114,036,665 104,148,985

IONIX TECHNOLOGY, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

For the Nine Months Ended
March 31,
2020 2019
CASH FLOWS FROM OPERATING ACTIVITIES
Net income $ 210,712 $ 205,071
Adjustments required to reconcile net income to net cash provided by
(used in) operating activities:
Depreciation and amortization 580,625 184,172
Deferred taxes 1,306 (15,732 )
Stock compensation for advisory services 79,891 -
Change in fair value of derivative liability (86,602 ) -
Loss on extinguishment of debt 15,074 -
Non-cash interest 351,474 -
Gain on disposal of property and equipment (7,018 ) -
Changes in operating assets and liabilities:
Accounts receivable - non-related parties 37,312 593,935
Accounts receivable - related parties (92,348 ) (22,607 )
Inventory 237,193 (774,776 )
Advances to suppliers - non-related parties (232,695 ) 13,826
Advances to suppliers - related parties (3,352 ) (114,802 )
Prepaid expenses and other current assets (150,496 ) (75,559 )
Accounts payable - non-related parties (83,000 ) (645,258 )
Accounts payable - related parties - (198,782 )
Advance from customers (52,380 ) (61,014 )
Accrued expenses and other current liabilities (164,326 ) 10,938
Net cash provided by (used in) operating activities 641,370 (900,588 )

CASH FLOWS FROM INVESTING ACTIVITIES
Acquisition of property, plant and equipment (193,610 ) (38,375 )
Proceeds received from sale of equipment 121,715 -
Cash received from acquisition - 687,591
Net cash provided by (used in) investing activities (71,895 ) 649,216

CASH FLOWS FROM FINANCING ACTIVITIES
Notes receivable 94,292 54,451
Proceeds from issuance of convertible notes payable 722,190 -
Return of capital to non-controlling interests - (58,155 )
Proceeds from (repayment of) loans from related parties (28,979 ) 591,766
Net cash provided by financing activities 787,503 588,062

Effect of exchange rate changes on cash (31,830 ) 46,668

Net increase in cash and cash equivalents 1,325,148 383,358

Cash and cash equivalents, beginning of period 509,615 111,462

Cash and cash equivalents, end of period $ 1,834,763 $ 494,820

Supplemental disclosure of cash flow information
Cash paid for income tax $ 154,538 $ 144,124
Cash paid for interests $ 102,457 $ 35,250

Non-cash investing and financing activities
Issuance of 15,000,000 shares of common stock in exchange for
95.14% ownership rights of a variable interest entity $ - $ 8,651,896
Issuance of common stock for advisory services $ 262,500 $ -
Issuance of 40,057 shares of common stock for conversion of
convertible notes $ 60,365 $ -
The accompanying notes are an integral part of these consolidated financial statements.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 5

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading

Top 5 Most Recently Viewed Articles

ING's Successful Share Buyback and New €1.6 Billion Plan

Updated Category News Views 246

ING Finalizes Share Buyback and Unveils New Distribution Strategy Recently, ING announced that it has successfully completed its comprehensive share buyback program. This initiative, which commenced earlier, concluded with the repurchase of an impressive total of 101,193,469 ordinary shares at an average price of €19.77, resulting in a total expenditure of approximately...

Continue Reading
Aicuris' Pritelivir Shows Promise for Immunocompromised Patients

Updated Category News Views 203

Breakthrough Results for Pritelivir in Immunocompromised Patients Pritelivir has distinguished itself in the realm of treatment for refractory Herpes Simplex Virus (HSV) infections among immunocompromised patients. The recent Phase 3 trial reported a statistically significant superiority in lesion healing compared to standard-of-care treatments, demonstrating the...

Continue Reading
Market Insights: Bitcoin's Stability Amidst Altcoin Declines

Updated Category News Views 213

Market Dynamics: Bitcoin Stands Firm as Altcoins Dwindle In a recent turn of events, leading altcoins such as Ethereum and XRP experienced significant price drops, indicating a potential shift in the cryptocurrency market's dynamics. This selloff occurred after a period of robust growth within the broader market, shaking investor confidence. Understanding the Market...

Continue Reading
American Rebel Holdings Partners with Ace Distributing in PA

Updated Category News Views 164

American Rebel Holdings Strengthens Beer Distribution Network Ace Distributing, a prestigious beer wholesaler with a rich history, has joined the American Rebel Light Beer family. This partnership marks a significant step in American Rebel's strategy to enhance its distribution network across Pennsylvania. The Partnership Breakdown American Rebel Holdings, Inc. (NASDAQ:...

Continue Reading
Core Natural Resources Delivers Strong Q3 Performance Insights

Updated Category News Views 143

Core Natural Resources Achieves Impressive Q3 Results Core Natural Resources, Inc. (NYSE: CNR) has just reported an exciting fiscal performance for its third quarter, showcasing substantial growth in net cash generated from operating activities and increased shareholder returns. Strong Financial Milestones The company generated net cash provided by operating activities...

Continue Reading